|
US4737462A
(en)
|
1982-10-19 |
1988-04-12 |
Cetus Corporation |
Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
|
|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
|
DE3689123T2
(de)
|
1985-11-01 |
1994-03-03 |
Xoma Corp |
Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US6080560A
(en)
|
1994-07-25 |
2000-06-27 |
Monsanto Company |
Method for producing antibodies in plant cells
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5855887A
(en)
|
1995-07-25 |
1999-01-05 |
The Regents Of The University Of California |
Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
|
|
EP0970128A1
(en)
|
1997-03-21 |
2000-01-12 |
Brigham And Women's Hospital |
Immunotherapeutic ctla-4 binding peptides
|
|
EP1082411A2
(en)
|
1998-06-02 |
2001-03-14 |
Dendreon Corporation |
Method for preparation and in vivo administration of antigen presenting cell composition
|
|
US6512162B2
(en)
|
1998-07-10 |
2003-01-28 |
Calgene Llc |
Expression of eukaryotic peptides in plant plastids
|
|
US20030167531A1
(en)
|
1998-07-10 |
2003-09-04 |
Russell Douglas A. |
Expression and purification of bioactive, authentic polypeptides from plants
|
|
ES2706547T3
(es)
|
1998-12-23 |
2019-03-29 |
Pfizer |
Anticuerpos monoclonales humanos para CTLA-4
|
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
|
NZ517202A
(en)
|
1999-08-24 |
2004-05-28 |
Medarex Inc |
Human CTLA-4 antibodies and their uses
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
CA2388432A1
(en)
|
1999-10-21 |
2001-04-26 |
Monsanto Company |
Post-translational modification of recombinant proteins produced in plants
|
|
AU1811801A
(en)
|
1999-12-03 |
2001-06-12 |
Dendreon Corporation |
Cryopreservation of antigen-loaded dendritic cells and their precursors in serum-free media
|
|
AU2001233027A1
(en)
|
2000-01-27 |
2001-08-07 |
Genetics Institute, Llc |
Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
|
|
US7060279B2
(en)
|
2000-03-30 |
2006-06-13 |
Dendreon Corporation |
Compositions and methods for dendritic cell-based immunotherapy
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
KR100944575B1
(ko)
|
2002-10-17 |
2010-02-25 |
젠맵 에이/에스 |
Ｃｄ20에 대한 인간 모노클로날 항체
|
|
DK1678314T3
(da)
|
2003-10-22 |
2012-12-03 |
Keck Graduate Inst |
Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
|
|
US9200079B2
(en)
|
2004-11-12 |
2015-12-01 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US20080196111A1
(en)
|
2005-03-18 |
2008-08-14 |
Innate Pharma S.A. |
Expression Vectors and Methods for Obtaining Nk Cell Specific Expression
|
|
US20100111973A1
(en)
|
2006-09-22 |
2010-05-06 |
Glenn Dranoff |
Methods for treating mica-related disorders
|
|
ES2550384T3
(es)
|
2008-12-18 |
2015-11-06 |
Dana-Farber Cancer Institute, Inc. |
NKG2D-Fc para la inmunoterapia
|
|
WO2012091756A1
(en)
|
2010-12-30 |
2012-07-05 |
Avidbiotics Corp. |
Non-natural mic proteins
|
|
LT2691417T
(lt)
|
2011-03-29 |
2018-10-25 |
Roche Glycart Ag |
Antikūno fc variantai
|
|
US8753640B2
(en)
*
|
2011-05-31 |
2014-06-17 |
University Of Washington Through Its Center For Commercialization |
MIC-binding antibodies and methods of use thereof
|
|
DK2760471T3
(en)
|
2011-09-30 |
2017-05-08 |
Dana Farber Cancer Inst Inc |
THERAPEUTIC PEPTIDES
|
|
JP6405242B2
(ja)
|
2012-02-07 |
2018-10-17 |
イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． |
Ｍｉｃａ結合剤
|
|
SG11201505896YA
(en)
|
2013-02-20 |
2015-09-29 |
Novartis Ag |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
|
WO2014144791A2
(en)
|
2013-03-15 |
2014-09-18 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
JP6450381B2
(ja)
|
2013-07-05 |
2019-01-09 |
ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション |
がんを処置するための可溶性ｍｉｃ中和モノクローナル抗体
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
IL292038B2
(en)
|
2014-04-23 |
2024-12-01 |
Juno Therapeutics Inc |
Methods for enriching or producing immune cell populations for adoptive therapy
|
|
WO2015179627A1
(en)
|
2014-05-21 |
2015-11-26 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer with anti bip or anti mica antibodies
|
|
EP3712171A1
(en)
|
2014-08-19 |
2020-09-23 |
Novartis AG |
Treatment of cancer using a cd123 chimeric antigen receptor
|
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對ｃｄ１９具專一性之抗體及嵌合抗原受體
|
|
BR112017008042A2
(pt)
|
2014-10-20 |
2017-12-26 |
Juno Therapeutics Inc |
métodos e composições para dosagem em terapia de célula adotiva
|
|
US20160208018A1
(en)
|
2015-01-16 |
2016-07-21 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for ror1
|
|
WO2016154585A1
(en)
|
2015-03-26 |
2016-09-29 |
Charles Sentman |
Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
|
|
EP3288569A4
(en)
|
2015-04-29 |
2018-12-19 |
Fred Hutchinson Cancer Research Center |
Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
|
|
ES2958720T3
(es)
|
2015-06-10 |
2024-02-13 |
Immunitybio Inc |
Células NK-92 modificadas para tratar el cáncer
|
|
MX2018006785A
(es)
|
2015-12-04 |
2018-11-09 |
Dana Farber Cancer Inst Inc |
Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer.
|
|
AU2016366677A1
(en)
|
2015-12-09 |
2018-07-26 |
Nantcell, Inc. |
Compositions and methods for treatment of HER2 positive metastatic breast cancer
|
|
WO2018073648A1
(en)
|
2016-10-19 |
2018-04-26 |
Novelogics Biotechnology, Inc. |
Antibodies to mica and micb proteins
|
|
EP3532091A2
(en)
|
2016-10-29 |
2019-09-04 |
H. Hoffnabb-La Roche Ag |
Anti-mic antibidies and methods of use
|
|
AU2018231193B2
(en)
|
2017-03-08 |
2021-07-22 |
Immunitybio, Inc. |
Modified NK-92 haNK003 cells for the clinic
|
|
CN117363636A
(zh)
|
2017-03-27 |
2024-01-09 |
新加坡国立大学 |
一种编码嵌合受体的多核苷酸
|
|
WO2019004550A1
(ko)
|
2017-06-26 |
2019-01-03 |
강원대학교 산학협력단 |
Mic-1 단백질에 특이적으로 결합하는 항체 및 이의 용도
|
|
US12036241B2
(en)
|
2017-07-19 |
2024-07-16 |
Fate Therapeutics, Inc. |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
|
KR20200035999A
(ko)
|
2017-08-04 |
2020-04-06 |
난트케이웨스트, 인크. |
Nk-92 세포를 이용한 백혈병의 치료 및 억제
|
|
EP4516896A3
(en)
|
2017-08-09 |
2025-05-14 |
Juno Therapeutics, Inc. |
Methods and compositions for preparing genetically engineered cells
|
|
US11066475B2
(en)
|
2017-11-01 |
2021-07-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
|
|
MA49911A
(fr)
|
2017-11-01 |
2020-06-24 |
Juno Therapeutics Inc |
Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
|
|
JP7351845B2
(ja)
|
2018-03-23 |
2023-09-27 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
|
|
KR102832008B1
(ko)
|
2018-07-31 |
2025-07-10 |
컬리난 미카 코퍼레이션 |
Mica/b 유출을 차단하는 항-mica/b 항체 및 사용 방법
|
|
BR112021002390A2
(pt)
|
2018-08-09 |
2021-05-11 |
Juno Therapeutics Inc |
processos para gerar células modificadas e suas composições
|
|
CN113330026A
(zh)
*
|
2018-10-23 |
2021-08-31 |
美真达治疗公司 |
Fc沉默的抗体药物缀合物(ADC)及其用途
|
|
EP4017876A4
(en)
|
2019-08-23 |
2023-09-06 |
Northwestern University |
MATERIALS AND METHODS FOR ACTIVATING ANTIGEN-SPECIFIC T CELL RESPONSES
|
|
EP4423140A4
(en)
|
2021-10-27 |
2025-10-01 |
Samyang Biopharm Usa Inc |
ANTI-MIC ANTIBODIES WITH VARIANT FC DOMAINS
|